Detection of Graft Versus Host Disease With [18F]F-AraG

Completed · Phase 1

Conditions studied: Graft Versus Host Disease

In brief

This is a single-center imaging study to determine utility of in vivo imaging with \[18F\]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. \[18F\]F-AraG PET scans will be compared to biopsy results to correlate T cell accumulation which is implicated in the disease. High risk patients will be followed to verify predictive potential of \[18F\]F-AraG.

Key facts

Study ID

NCT03367962

Run by

CellSight Technologies, Inc.

People needed

9

Starts

2018-05-15

Expected to finish

2023-10-21

Last updated by the study team

2025-12-08

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must be 21 years of age or older.
• Must understand and voluntarily have signed an Informed Consent after its contents have been fully explained.
• For patients highly suspected to have aGVHD and requiring systemic therapy, informed consent should be signed after biopsy taken to support clinical diagnosis.
• For patients at high risk for developing aGVHD, informed consent should be signed prior to transplant.
• For healthy volunteers only: Must have no known medical problems that would make undergoing the scan hazardous to the health of the patient or interfere with the results. In particular subjects should not have any cardiac or immunological disorders as these would likely affect the scan results. Subjects should have had a full physical exam within 6 months of the study. If healthy volunteers have not had a full medical exam within 6 months of the study, one of the nuclear medicine physicians will conduct the medical exam prior to any study procedures.
• For patients highly suspected to have aGVHD and requiring systemic therapy only: Taking steroid treatment for suspected aGVHD for 3 days or less.
• For patients at high risk for developing aGVHD only: Recipients of myeloablative or reduced intensity allogeneic transplants using either bone marrow or peripheral blood stem cells from HLA-matched or HLA-mismatched related or unrelated donors (protocols 9142, 9022, 9924) who have not yet been placed on any therapy for acute GVHD.

You may not qualify if…

• Pregnant or nursing
• Individuals with known or suspected substance abuse, obtained by self-reporting.
• Uncontrolled infection
• Relapsed/persistent malignancy
• Currently receiving immunotherapy

Where it is running

• Stanford Hospital — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.